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History(8)
in the recent decay 
major advances have been made in the 
development of Genome Editing (GE) 
methods 
the first successful editing of a 
mammalian genome was performed on 
mice in the 1980
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Introduction
Genome editing (is a technique for) 
Deleting 
Replacing 
Adding
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(8)
5International regulatory landscape and integration of corrective genome editing into in vitro fertilization(1) High-Content Analysis of  CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells
(1)
Technology GE
1.  microRNA & siRNA 
2.       Antisense Oligonucleotides (ASOs)      
3.  Nuclease ZFN 
TALEN  
CRISPER-Cas9
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  Zinc Finger Nuclease (ZFN) 
  Transcription Activator- Like Effector Nucleases 
(TALEN) 
 Clustered Regulatory Interspersed Short Palindromic   
Repeats (CRISPR)  
 These methods differ in the way they recognize a target     
location.
The more commonly known Nucleases are (8)
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Application
Disease Modeling 
Animal Models 
Target Disease 
Gene Therapy 
iPSCs (Induced Pluripotent Stem Cells) 
cancer models
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9Advances in CRISPR-Cas9 genome engineering/ lessons learned from RNA interference
Timeline of milestones (2)
RNAi
CRISPER /Cas9
Timeline of GE
✦ 2011 = ZFN pig and cattle 

✦ 2012 =TALEN = pig 

✦ 2013 =ZFN and TALEN = 
pig

✦ 2014 = CRISPR/Cas9  =pig 
and sheep 

✦ 2015 = TALEN = cattle and 
goat
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Gene targeting, genome editing: from Dolly to editors 
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2000-2002 2002-2004 2004-2006 2006-2008
2008-2010 2010-2012 2012-2014 2014-2016
Genome editing pathway(1)
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International regulatory landscape and integration of corrective genome editing into in vitro fertilization  
Advances in genome editing technology and its promising application in evolutionary and ecological studies  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High-Content Analysis of CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells
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pathway of Nuclease 
1 = microRNA & siRNA
2   =   ASOs
4 =  TALEN
3  =    ZFN
5 = CRISPER/Cas 9
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Advances in CRISPR-Cas9 genome engineering/ lessons learnd from RNA interferencee
1= microRNA
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(2)
1= siRNA
Silencing disease genes in the laboratory and the clinic (22)
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3 = ASO
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Silencing disease genes in the laboratory and the clinic (22)
Genome Engineering With Zinc-Finger Nucleases
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3= ZFN
(21) 
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases(18)
4 =TALEN
20
5= CRISPER/
Cas 9
Advances in CRISPR-Cas9 genome engineering/ lessons learnd from RNA interferencee
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structure of  CRISPER Cas9(7)
Efficient In Vivo Genome Editing Using RNA-Guided Nuclease
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  Cas9 protein 
  guide RNA 
  tracer RNA 
  PAM(proto spacer adjacent 
motif) NGG
comparison  
be tween d i ffe ren t genome ed i t ing 
technologies
ZFN
TALEN
CRISPER
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Feature ZFN TALEN CRISPR/Cas9
Efficiency 12% 76% 81%
Off -target effect more potential off-target 
effect than  TALENs
less observed  more potential off target 
than  other 
  methylation
sensitive
sensitive sensitive Not sensitive
 target DNA
recognition
Zinc  fingers (ZFs)  Repeat variable diresidues 
(RVDs)
crRNA or sgRND
 Minimum number of DNA
base be recognized
Triple Single Single
          Size of recognized
DNA  sequences
9-18 bp (8-13 bp)*2 20 bp +NGG
Cytotoxicity High Low Low
  advantage
 (CRISPER-Cas9 than
 (other
High efficiency Very high efficiency and 
rapid construction and easy 
delivery
 Disadvantage More difficult to assemble 
than CRISPR and remaining 
possibility of off target cleavage
Off-target cleavage possibly 
more frequent than ZFN and 
TALEN 
Target range Limited by range and 
context-dependence of ZF 
modules 
Limited by PAM sequence   
(potentially unlimited)
 Success rate of
nuclease design
Low High High
 Made of action DNA breaked by protein- 
DNA  recognition 
DNA break targeted by 
protein-DNA  recognition 
DNA break targeted by 
RNA-DNA  recognition 
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Feature RNAi CRISPR/Cas9
 Mode of action
Knock down gene at mRNA  
or non coding RNA level
Modifies gene (via knock out /
knock in )at genomic DNA  level
cytoplasm nucleus 
 Duration of effect Transient (siRNA) permanent 
heritable change genome  
Efficiency Typically  induces >75% 
knock down
Typically induces 10-40% 
editing per allele
 Design of functional
components Gene employ reagent targeted 
all along transcript
Can employ  only reagent with 
targets adjacent  to PAM  and (for 
gene knockout) in critical exon 
Target  substrate
RNA DNA
 Gene expression modulation
knockdown 
knockdown ,  
over expression and 
  knockout
 library creation from genomic
DNA/DNA Yes No
Accessory proteins RISC Cas9
comparison of approaches for gene knock down & gene knock out (14)
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Applications of  CRISPR–Cas systems in neuroscience1
26
(6)
Application
Disease Modeling 
Animal Models 
Target Disease 
Gene Therapy 
iPSCs (Induced Pluripotent Stem Cells) 
cancer models
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Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges 
Induced Pluripotency and Gene Editing in  Disease Modeling
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Neurological  Diseases 
Hematological Diseases 
Telomere  & Mitochondrial Diseases   
Metabolic Diseases   
Epigenetic Diseases  
Cardiovascular Diseases   
other Diseases
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rabbits 
(with  IL2 , RAG1 , RAG2  
knockout) 
hamsters  
(with STAT knock out )
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 Novel genome-editing tools to model and correct primary immunodeficiencies
Animal Models (19)
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference 
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 (2)
(gene therapy & disease modeling )(17)
Genome-editing tools for stem cell biology 
32
Development and potential applications of  CRISPR-Cas9 genome editing technology in sarcoma
33
Modeling cancer with CRISPER-Cas9(10)
Applications of CRISPR–Cas systems in neuroscience
34
The databases to design CRISPR/Cas9(6)
CrisperGE(9)
CrisprGE: a central hub of CRISPR/Cas-based genome editing 
35
Efficient In Vivo Genome Editing Using RNA-Guided Nuclease (7)
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Efficient In Vivo Genome Editing Using RNA-Guided Nuclease
(15)A Mouse Geneticist’s Practical Guide to CRISPR Applications 
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schematic of U6 ABCB1 sgRNA_CMV Cas9 -GFP expression 
 in single plasmid system (10)
Development and potential applications of  CRISPR-Cas9 genome editing technology in sarcoma
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strategy for generation of mouse PrP knock out clones on CRISPER/Cas9 -system 
CRISPR-Cas9-Based Knockout of the Prion Protein and Its Effect on the Proteome 
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(11)
Conclusions (5)
40
Applications of genome editing are still in their early stages.

Hopefully in the near future,

the application and replacement of particular regulation methods can 
also be successful and

in high-throughput manner, making the exploration of gene functions 
more precise and in-depth. Amazingly,

epigenetic regulation of genes by this technology will possibly open 

a new means in the field of functional epigenetic.
41
By taking advantages of these genome editing systems, 
we are now able to extend functional mechanistic studies to more 
research fields.
 Linked by technology,  
molecular  biologists  and  ecologists  will  now be  able  to  better 
cooperate to explore the interesting and important issues, 
 such as 
animal  social  behavior,  and  mechanisms  of  biodiversity 
maintenance. 
Conclusions
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